GU Cancers 2024 | KEYNOTE-057 cohort C: pembrolizumab with favezelimab or vibostolimab in NMIBC

In cohort A of the Phase II KEYNOTE-057 study (NCT02625961), pembrolizumab had preliminary efficacy in patients with Bacillus Calmette-Guérin (BCG)–unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Girish Kulkarni, MD, PhD, University of Toronto, Ontario, Canada, provides an overview of the cohort C portion of the trial. In addition to pembrolizumab, patients will also receive favezelimab, a LAG-3 inhibitor, or vibostolimab, a TIGIT inhibitor, in the hopes of enhancing the complete response rate in patients. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.